Medivation Inc (MDVN)

neg -0.49
Today's Range: 57.50 - 58.85 | MDVN Avg Daily Volume: 3,689,600
Last Update: 05/03/16 - 3:59 PM EDT
Volume: 3,658,521
YTD Performance: 20.05%
Open: $57.96
Previous Close: $58.01
52 Week Range: $26.41 - $66.40
Oustanding Shares: 164,233,527
Market Cap: 9,492,697,861
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 9 9 8
Moderate Buy 0 0 0 0
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.62 1.62 1.55
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 39.32
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
39.32 39.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
84.93% -7.49% 119.06%
Revenue 32.80 4.20 0.72
Net Income -11.50 -6.90 0.00
EPS -9.80 -6.50 0.00
Earnings for MDVN:
Revenue 0.94B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.20 $0.25 $1.11 $1.95
Number of Analysts 2 2 3 3
High Estimate $0.22 $0.27 $1.19 $2.35
Low Estimate $0.19 $0.24 $1.03 $1.48
Prior Year $0.03 $0.23 $0.68 $1.11
Growth Rate (Year over Year) 583.33% 8.51% 62.75% 75.90%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Apr 19, 2016 | 7:03 AM EDT
MDVN was upgraded from Hold to Buy, Canaccord Genuity said. $70 price target. Breast and Ovarian cancer treatments can drive growth.&nb...
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
This sort of action is needed periodically.
Medivation is surging as Wall Street scouts the Big Pharma front for discounted M&A opportunities.
Jan 27, 2016 | 7:15 AM EST
MDVN was downgraded to Hold, Canaccord Genuity said. $45 price target. Xtandi growth is slowing. 
Apr 20, 2015 | 7:23 AM EDT
MDVN was downgraded from Outperform to Neutral, Credit Suisse said. $115 price target. New analyst believes the company is facing growt...

3 Biotech Bounce Trades Real Money Pro($)

Chart setups in Celgene, Medivation and AMAG Pharmaceuticals.
It's the only way to deal with this market.
Sep 24, 2014 | 6:45 AM EDT
MDVN was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $110 price target.

Columnist Conversations

Coming up!
National Oilwell Varco (NOV) is a big energy equipment maker in the cyclical doldrums. Its balance sheet is st...
Among the famed Danaher (DHR) wannabes in mid-cap industrial land, Colfax (CFX) continues to get pushed around...
Applied Materials is also on a four day losing streak that has pushed shares below the April lows. This f...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.